But in a recent randomized, double-blinded, placebo-controlled trial of 160 older adult patients within 72 h after the onset of mild COVID-19 symptoms, early administration of high-titer CP against SARS-CoV-2 reduced the progression of COVID-19 significantly by a relative risk of 0.52 (95% confidence interval [CI], 0.29 to 0.94; p = 0.03) [14]. This evidence concerns the gene CP and COVID-19.